Inhaled Long-Acting Beta Agonist(Sanofi)은 Chronic Obstructive Pulmonary Disease 표적 치료제로, Chronic Obstructive Pulmonary Disease 영역에서 개발·상용화 중입니다. 작용기전: of LAMA is bronchodilation through antagonism of M 3 muscarinic acetylcholine (ACh) receptors (mAChR) on airway smooth muscle. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 7.6% (ClinicalTrials.gov NCT03250689). 차별점: Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial.
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Active
Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial
of LAMA is bronchodilation through antagonism of M 3 muscarinic acetylcholine (ACh) receptors (mAChR) on airway smooth muscle
Apoptosis was induced in Jurkat T cells by UV irradiation (100 mJ/cm 2 ) and in murine thymocytes by dexamethasone (1 µM, 4
biomarkers are established therapeutic targets in asthma and non-asthmatic eosinophilic bronchitis (NAEB), bu
downregulation in TNF-α levels by about 60 % and improvement inflammatory lesions in both the airway and alveolar region
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Inhaled Long-Acting Beta Agonist(Sanofi)은 Chronic Obstructive Pulmonary Disease 표적 치료제로, Chronic Obstructive Pulmonary Disease 영역에서 개발·상용화 중입니다. 작용기전: of LAMA is bronchodilation through antagonism of M 3 muscarinic acetylcholine (ACh) receptors (mAChR) on airway smooth muscle. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 7.6% (ClinicalTrials.gov NCT03250689). 차별점: Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial.
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Active
Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial
of LAMA is bronchodilation through antagonism of M 3 muscarinic acetylcholine (ACh) receptors (mAChR) on airway smooth muscle
Apoptosis was induced in Jurkat T cells by UV irradiation (100 mJ/cm 2 ) and in murine thymocytes by dexamethasone (1 µM, 4
biomarkers are established therapeutic targets in asthma and non-asthmatic eosinophilic bronchitis (NAEB), bu
downregulation in TNF-α levels by about 60 % and improvement inflammatory lesions in both the airway and alveolar region
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.